USFDA accepts regulatory submission for tanezumab for management of chronic pain due to osteoarthritis Medical Dialogues Bureau7 March 2020 4:30 AM GMTTanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF)...